Generic drug: caplacizumab-yhdp
Brand name: Cablivi
What is Cablivi (caplacizumab-yhdp), and how does it work?
Cablivi (caplacizumab-yhdp) is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
What are the side effects of Cablivi?
Common side effects of Cablivi include:
- bleeding gums,
- injection site reactions (bleeding, itching),
- back pain,
- muscle pain,
- numbness and tingling,
- urinary tract infection (UTI),
- blood in the urine,
- abnormal vaginal bleeding,
- shortness of breath, and
What is the dosage for Cablivi?
Recommended Dose And Schedules
Cablivi should be administered upon initiation of plasma exchange therapy. The recommended dose of Cablivi is as follows:
- First day of treatment: 11 mg bolus intravenous injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on day 1.
- Subsequent days of treatment during daily plasma exchange: 11 mg subcutaneous injection once daily following plasma exchange.
- Treatment after plasma exchange period: 11 mg subcutaneous injection once daily continuing for 30 days following the last daily plasma exchange. If after initial treatment course, sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.
Discontinue Cablivi if the patient experiences more than 2 recurrences of aTTP, while on Cablivi.
If a dose of Cablivi is missed during the plasma exchange period, it should be given as soon as possible. If a dose of Cablivi is missed after the plasma exchange period, it can be administered within 12 hours of the scheduled time of administration. Beyond 12 hours, the missed dose should be skipped and the next daily dose administered according to the usual dosing schedule.
Discontinuation For Surgery And Other Interventions
Withhold Cablivi treatment 7 days prior to elective surgery, dental procedures, or other invasive interventions.
Reconstitution And Administration Instructions
The first dose of Cablivi should be administered by a healthcare provider as a bolus intravenous injection. Administer subsequent doses subcutaneously in the abdomen. Avoid injections around the navel. Do not administer consecutive injections in the same abdominal quadrant.
Patients or caregivers may inject Cablivi subcutaneously after proper training on the preparation and administration of Cablivi, including aseptic technique.
- Ensure the Cablivi vial and diluent syringe are at room temperature.
- Reconstitute Cablivi before administration using the provided syringe containing 1 mL Sterile Water for Injection, USP, to yield an 11 mg/mL single-dose solution.
- Using aseptic technique throughout the preparation of the solution, attach the vial adapter to the vial containing Cablivi.
- Remove the plastic cap from the syringe and attach it to the vial adapter by twisting it clockwise until it cannot twist any further.
- Slowly push the syringe plunger down until the syringe is empty. Do not remove the syringe from the vial adapter.
- Gently swirl the vial until the cake or powder is completely dissolved. Do not shake.
- Visually inspect that the reconstituted solution is clear and colorless.
- Withdraw all of the clear, colorless reconstituted solution from the vial into the syringe. Label the Cablivi syringe.
- Administer the full amount of reconstituted solution.
- For the initial intravenous injection, if using an intravenous line, the glass syringe should be connected to a standard Luer lock (and not a needleless connector) and flushed with either 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP.
- Use the Cablivi solution immediately. If not, use Cablivi within 4 hours after reconstitution when stored in the refrigerator at 2°C to 8°C (36°F to 46°F).
What drugs interact with Cablivi?
Concomitant Use Of Anticoagulants
Concomitant use of Cablivi with any anticoagulant may increase the risk of bleeding. Assess and monitor closely for bleeding with concomitant use.
Is Cablivi safe to use while pregnant or breastfeeding?
- There are no available data on Cablivi use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, there are potential risks of hemorrhage in the mother and fetus associated with use of Cablivi.
- There is no information regarding the presence of caplacizumab-yhdp in human milk, the effects on the breastfed child or the effects on milk production.
- The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Cablivi and any potential adverse effects on the breastfed child from Cablivi, or from the underlying maternal condition.
Cablivi (caplacizumab-yhdp) is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. Common side effects of Cablivi include nosebleed, headache, bleeding gums, fatigue, fever, injection site reactions (bleeding, itching), back pain, muscle pain, numbness and tingling, urinary tract infection (UTI), blood in the urine, abnormal vaginal bleeding, shortness of breath, and hives.
Multimedia: Slideshows, Images & Quizzes
A Visual Guide to Deep Vein Thrombosis (DVT)
Deep vein thrombosis (DVT) is a dangerous and sometimes fatal blood clot that occurs deep within the lower leg or thigh....
Blood Disorders: Types, Symptoms, and Treatments
Some blood disorders are forms of cancer. Others are benign. Find out what happens and why.
Healthy Eating: Foods That Help Increase Blood Flow Circulation
Good blood flow circulation occurs when you eat the right foods. Choose cayenne pepper, beets, berries, fatty fish, pomegranate,...
Picture of Henoch-Schonlein Purpura
Henoch-Schonlein purpura. Henoch-Schonlein purpura (HSP) is a disease that involves inflammation which causes blood vessels in...
Hemophilia Quiz: Test Your IQ of This Blood Disorder
What happens within the body in a person who has hemophilia? Take this quiz to learn about this rare blood disorder.
DVT (Deep Vein Thrombosis) and Pulmonary Embolism (PE) Quiz
Take the Deep Vein Thrombosis and Pulmonary Embolism Quiz to learn causes, symptoms, and treatments for these two dangerous...
Related Disease Conditions
How Long Do Thrombosed External Hemorrhoids Last?
Many thrombosed external hemorrhoids may go away within a few weeks. Pain may improve within 7-10 days without surgery and may disappear within 2-3 weeks.
Thrombocytopenia (Low Platelet Count)
Thrombocytopenia (low platelet count) refers to a decreased number of platelets in the blood. Symptoms of thrombocytopenia include: Increased bruising Spontaneous bleeding Small, purple spots under the skin called purpura There are many causes of thrombocytopenia such as decreased platelet production (viral infections for example rubella, mumps, chickenpox, hepatitis C, and HIV); increased platelet destruction or consumption (for example sulfonamide antibiotics, heparin, blood transfusions, and lupus); or increased splenic sequestration (enlarged spleen due to conditions, for example, liver disease, blood cancers, and more). Treatment of thrombocytopenia depends on the cause.
Deep Vein Thrombosis (DVT, Blood Clot in the Legs)
Deep vein thrombosis (DVT) is a blood clot in the deep veins, and can be caused by broken bones, trauma to a limb, immobility, medications, smoking, cancer, genetic predisposition, and cancer. Symptoms and signs of a deep vein thrombosis in a leg are swelling, tenderness, redness, warmth, and pain. Treatments for DVT include medications and surgery.
Phlebitis is the inflammation of a vein. Thrombophlebitis is when a blood clot causes the inflammation. Phlebitis can be superficial or deeper in the veins. A blood clot deep in a vein is deep vein thrombosis (DVT). Some of the common causes of phlebitis include prolonged inactivity, varicose veins, trauma to a vein, underlying cancers, clotting disorders, and other causes. Symptoms of phlebitis may be mild (pain, tenderness, redness, or bulging of a vein. Treatment of phlebitis depends on the cause.
Henoch-Schonlein Purpura (HSP)
Henoch-Schonlein purpura (HSP or anaphylactoid purpura), a type of blood vessel inflammation, results in rash, arthritis, and occasional abdominal cramping. HSP often resolves on its own. Joint pain may be treated with anti-inflammatory and cortisone medications.
Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic means that the cause of the condition isn't known. Thrombocytopenic means there's a lower than normal number of platelets in the blood. Purpura refers to purple bruises caused by bleeding under the skin. Idiopathic thrombocytopenic purpura (ITP) is a bleeding condition in which the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets.
Actinic Purpura Vs Senile Purpura
Senile purpura, also called actinic purpura, is a benign skin condition that commonly affects older adults. Actinic purpura results from sun-induced damage to the connective tissue of the dermis (deeper layers of the skin) combined with the fact that the blood vessels become thinner and more fragile and collagen decreases with increasing age.
DVT (Deep Vein Thrombosis) During Pregnancy
Deep vein thrombosis or DVT is a condition in which a blood clot becomes embedded in one of the deep veins of the arms, thighs, pelvis, or lower legs. Warning signs and symptoms of DVT include pain, warmth, redness, swelling, leg cramps, and worsening leg pain in the affected extremity. Many conditions and other factors can cause DVTs, for example, during pregnancy including postpartum (6-8 weeks after delivery of the baby), obesity, heart attacks or heart failure, cancer, birth control pills (oral contraceptives), recent surgery, high altitudes, and advanced age. Treatment guidelines for DVT diagnosed during pregnancy is anticoagulation (anti-clotting) drugs, usually, low-molecular-weight heparins. DVT treatment may need to be continued postpartum. Warfarin (Coumadin, Jantoven) should not be used to treat DVT during pregnancy because it can harm the developing fetus.
What Are the Symptoms of Thrombosis?
Depending on the location of the thrombus or blood clot, thrombosis may include pain and warmth in the area of the clot, or chest pain and difficulty breathing if the clot is near the lungs, among other symptoms.
Treatment & Diagnosis
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.